2025 United States Acute Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 United States Acute Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States acute migraine drugs market are Teva Pharmaceuticals, Pfizer, Novartis, and Eli Lilly and Company. These companies hold significant market shares, contributing to the development and commercialization of key migraine treatments. Teva is advancing its portfolio with FDA accepted supplemental Biologics License Applications for drugs like AJOVY® and continues to focus on both pediatric and adult migraine prevention. Pfizer and Novartis are leading players known for their development of triptans and advancing CGRP inhibitors, which are demonstrating rapid market growth due to their efficacy and safety profiles. Eli Lilly holds a substantial share with Emgality®, a CGRP inhibitor regarded as highly effective in migraine prevention.
These companies are driving market expansion through innovative drug delivery systems and new drug approvals. For instance, Axsome Therapeutics recently gained FDA approval for its oral migraine treatment Symbravo, signaling competitive advancements in acute migraine therapy. Satsuma Pharmaceuticals introduced ATZUMI, a nasal powder formulation using novel delivery technology, highlighting the shift toward more patient-friendly options. The acute migraine treatment market in the U.S. is expected to maintain steady growth driven by increased awareness, novel therapies like CGRP antagonists, and investments in R&D from these established pharma leaders.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States acute migraine drugs market are Teva Pharmaceuticals, Pfizer, Novartis, and Eli Lilly and Company. These companies hold significant market shares, contributing to the development and commercialization of key migraine treatments. Teva is advancing its portfolio with FDA accepted supplemental Biologics License Applications for drugs like AJOVY® and continues to focus on both pediatric and adult migraine prevention. Pfizer and Novartis are leading players known for their development of triptans and advancing CGRP inhibitors, which are demonstrating rapid market growth due to their efficacy and safety profiles. Eli Lilly holds a substantial share with Emgality®, a CGRP inhibitor regarded as highly effective in migraine prevention.
These companies are driving market expansion through innovative drug delivery systems and new drug approvals. For instance, Axsome Therapeutics recently gained FDA approval for its oral migraine treatment Symbravo, signaling competitive advancements in acute migraine therapy. Satsuma Pharmaceuticals introduced ATZUMI, a nasal powder formulation using novel delivery technology, highlighting the shift toward more patient-friendly options. The acute migraine treatment market in the U.S. is expected to maintain steady growth driven by increased awareness, novel therapies like CGRP antagonists, and investments in R&D from these established pharma leaders.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
